MX368539B - Derivados de 2-acilaminotiazol o su sal. - Google Patents

Derivados de 2-acilaminotiazol o su sal.

Info

Publication number
MX368539B
MX368539B MX2015011202A MX2015011202A MX368539B MX 368539 B MX368539 B MX 368539B MX 2015011202 A MX2015011202 A MX 2015011202A MX 2015011202 A MX2015011202 A MX 2015011202A MX 368539 B MX368539 B MX 368539B
Authority
MX
Mexico
Prior art keywords
optionally substituted
bladder
muscarinic
receptor
alkyl
Prior art date
Application number
MX2015011202A
Other languages
English (en)
Other versions
MX2015011202A (es
Inventor
Maeda Jun
Negoro Kenji
Takahashi Taisuke
Inagaki Yusuke
Tanaka Hiroaki
Yokoyama Kazuhiro
takamatsu Hajime
Koike Takanori
Tsukamoto Issei
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2015011202A publication Critical patent/MX2015011202A/es
Publication of MX368539B publication Critical patent/MX368539B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Abstract

Problema Se proporciona un compuesto que es de utilidad como un ingrediente activo de una composición farmacéutica para el tratamiento de disfunciones de almacenamiento, disfunciones de evacuación y enfermedades del tracto urinario inferior. [Medios de solución] Los presentes inventores hallaron que un derivado de tiazol con pirazin-2-carbonilamino sustituido en la posición 2 es un excelente modulador alostérico positivo del receptor muscarínico M3 y es de utilidad como un agente para prevenir y/o tratar enfermedades de la vejiga o del tracto urinario, relacionadas con la contracción de la vejiga por el receptor muscarínico M3, completando así la presente invención. El derivado de 2-acilaminotiazol o una de sus sales de la presente invención se puede usar como un agente para prevenir y/o tratar enfermedades de la vejiga o del tracto urinario, relacionadas con la contracción de la vejiga por el receptor muscarínico M3, por ejemplo, disfunciones de evacuación como vejiga hipoactiva.
MX2015011202A 2013-02-28 2014-02-27 Derivados de 2-acilaminotiazol o su sal. MX368539B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013039964 2013-02-28
PCT/JP2014/054803 WO2014133056A1 (ja) 2013-02-28 2014-02-27 ２－アシルアミノチアゾール誘導体またはその塩

Publications (2)

Publication Number Publication Date
MX2015011202A MX2015011202A (es) 2016-05-18
MX368539B true MX368539B (es) 2019-10-07

Family

ID=51428316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011202A MX368539B (es) 2013-02-28 2014-02-27 Derivados de 2-acilaminotiazol o su sal.

Country Status (24)

Country Link
US (1) US9562044B2 (es)
EP (1) EP2963036B1 (es)
JP (1) JP6183451B2 (es)
KR (1) KR102164821B1 (es)
CN (1) CN105008353B (es)
AR (1) AR094921A1 (es)
AU (1) AU2014221726B2 (es)
BR (1) BR112015020963B1 (es)
CA (1) CA2902302C (es)
EA (1) EA027179B1 (es)
ES (1) ES2748402T3 (es)
HK (1) HK1214255A1 (es)
IL (1) IL240764A0 (es)
MX (1) MX368539B (es)
MY (1) MY190361A (es)
PH (1) PH12015501899B1 (es)
PL (1) PL2963036T3 (es)
PT (1) PT2963036T (es)
SA (1) SA515360956B1 (es)
SG (1) SG11201506713TA (es)
TW (1) TWI647227B (es)
UA (1) UA118445C2 (es)
WO (1) WO2014133056A1 (es)
ZA (1) ZA201506296B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201609684SA (en) * 2014-05-28 2016-12-29 Astellas Pharma Inc Pyridine derivative
SG10202000463YA (en) * 2014-06-06 2020-02-27 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof
KR20170042608A (ko) 2014-08-26 2017-04-19 아스텔라스세이야쿠 가부시키가이샤 2-아미노티아졸 유도체 또는 그의 염
CN107001273B (zh) * 2014-12-05 2020-05-12 安斯泰来制药株式会社 吡啶衍生物
AR102849A1 (es) * 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
MX2017013896A (es) * 2015-04-28 2018-03-15 Astellas Pharma Inc Composicion farmaceutica para administracion oral.
WO2016183676A1 (en) * 2015-05-20 2016-11-24 Kent Imaging Automatic compensation for the light attenuation due to epidermal melanin in skin images
RU2709496C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения аватромбопага
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466912B1 (en) 2002-01-18 2013-04-24 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CA2529686C (en) * 2003-07-17 2010-06-15 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
JP4774995B2 (ja) * 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
JP4665769B2 (ja) * 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
PT2598483T (pt) * 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos

Also Published As

Publication number Publication date
HK1214255A1 (zh) 2016-07-22
ZA201506296B (en) 2017-11-29
KR102164821B1 (ko) 2020-10-13
BR112015020963A2 (pt) 2017-07-18
AU2014221726A1 (en) 2015-09-10
JPWO2014133056A1 (ja) 2017-02-02
IL240764A0 (en) 2015-10-29
TWI647227B (zh) 2019-01-11
EA027179B1 (ru) 2017-06-30
ES2748402T3 (es) 2020-03-16
MY190361A (en) 2022-04-17
EP2963036A1 (en) 2016-01-06
MX2015011202A (es) 2016-05-18
CN105008353B (zh) 2017-11-10
US20160002218A1 (en) 2016-01-07
PH12015501899A1 (en) 2016-01-04
UA118445C2 (uk) 2019-01-25
SG11201506713TA (en) 2015-09-29
BR112015020963B1 (pt) 2020-10-27
KR20150120516A (ko) 2015-10-27
CA2902302A1 (en) 2014-09-04
TW201522330A (zh) 2015-06-16
PT2963036T (pt) 2019-10-15
AR094921A1 (es) 2015-09-09
US9562044B2 (en) 2017-02-07
EP2963036B1 (en) 2019-08-28
CN105008353A (zh) 2015-10-28
EA201591391A1 (ru) 2016-01-29
CA2902302C (en) 2021-03-09
PH12015501899B1 (en) 2016-01-04
AU2014221726B2 (en) 2018-06-28
PL2963036T3 (pl) 2019-12-31
WO2014133056A1 (ja) 2014-09-04
SA515360956B1 (ar) 2016-12-07
JP6183451B2 (ja) 2017-08-23
EP2963036A4 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
PH12015501899A1 (en) 2-cylaminothiazole derivative and salt thereof
TR201903892T4 (tr) Diyabet ve obezitenin tedavisinde kullanılan dihidrobenzofuran bileşikleri.
PH12016501614A1 (en) Heterocyclic compound
JO3114B1 (ar) مركبات بيريدازينون
MX2015011273A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
MY178760A (en) Monocyclic pyridine derivative
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
PH12015501037A1 (en) Pyridine derivative
MX368178B (es) Compuestos de ácido dimetilbenzoico.
ECSP14013249A (es) Derivados de anilina, su preparación y su aplicación terapéutica
AR080969A1 (es) Compuesto biciclico
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
TR201901986T4 (tr) Heterosiklik bileşik.
EP3769757A3 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
MX2015006930A (es) Compuestos de isoxazol amina sustituidos como inhibidores de scd1.
PH12016501645A1 (en) Aminopyrazolone derivative
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
UA106741C2 (uk) Піридазинони
AR096563A1 (es) Compuesto heterocíclico
TH161045B (th) สารประกอบเฮเทอโรไซคลิกที่ถูกแทนที่ด้วยเอมีดที่มีประโยชน์เป็นโมดูเลเตอร์ ของการตอบสนอง il-12, il-23 และ/หรือ ifn?

Legal Events

Date Code Title Description
FG Grant or registration